BACKGROUND Moyamoya disease is a rare progressive, occlusive cerebrovascular disorder characterised by stenosis of the internal carotid arteries. The goal of surgical intervention in Moyamoya disease is to establish collateral blood flow with the intention of revascularising previously ischaemic areas of the brain. The most common procedure being Encephaloduroarteriosynangiosis (EDAS). Anaesthetic management of patients with Moyamoya Disease (MMD) focuses on maintenance of adequate cerebral blood flow, normalisation of intracranial pressure and avoidance of both cerebral vasoconstriction and vasodilatation. Dexmedetomidine is a short-acting alpha-2-adrenoceptor agonist which decreases mean arterial pressure, heart rate and has reasonable analgesic effect. The objective was to study the effect of Dexmedetomidine as an anaesthetic adjuvant in Moyamoya disease patients. MATERIALS AND METHODS The study design is a retrospective descriptive study of 10 cases of Moyamoya disease, who underwent EDAS procedure at our tertiary care hospital between February 2015 and October 2017. RESULTS In all the 10 patients, intraoperative haemodynamic parameters and complications were noted. The mean heart rate and blood pressure in all the patients remained within 15% of baseline and steady during the study period, i.e. intraoperatively and 20 minutes postoperatively. CONCLUSION The effect of dexmedetomidine on the haemodynamic and recovery profile of these patients was found to be beneficial.